Cost Effectiveness Analysis (CEA) of Nivolumab in 2nd Line Non-Small Cell Lung Cancer (NSCLC) with Non-Squamous Histology (NSQ) Using A Mixed Comparator of Docetaxel and Pemetrexed in An Australian Setting
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.205
https://www.valueinhealthjournal.com/article/S1098-3015(17)30539-9/fulltext
Title :
Cost Effectiveness Analysis (CEA) of Nivolumab in 2nd Line Non-Small Cell Lung Cancer (NSCLC) with Non-Squamous Histology (NSQ) Using A Mixed Comparator of Docetaxel and Pemetrexed in An Australian Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30539-9&doi=10.1016/j.jval.2017.08.205
First page :
A434
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
185